Search results

507 results

Sorted by Date . Sort by Relevance

  1. Challenging behaviour and learning disabilities: prevention and interventions for people with learning disabilities whose behaviour challenges (NG11)

    This guideline covers interventions and support for children, young people and adults with a learning disability and behaviour that challenges. It highlights the importance of understanding the cause of behaviour that challenges, and performing thorough assessments so that steps can be taken to help people change their behaviour and improve their quality of life. The guideline also covers support and intervention for family members or carers.

  2. Violence and aggression: short-term management in mental health, health and community settings (NG10)

    This guideline covers the short-term management of violence and aggression in adults (aged 18 and over), young people (aged 13 to 17) and children (aged 12 and under). It is relevant for mental health, health and community settings. The guideline aims to safeguard both staff and people who use services by helping to prevent violent situations and providing guidance to manage them safely when they occur.

  3. Medicines optimisation: the safe and effective use of medicines to enable the best possible outcomes (NG5)

    This guideline covers safe and effective use of medicines in health and social care for people taking 1 or more medicines. It aims to ensure that medicines provide the greatest possible benefit to people by encouraging medicines reconciliation, medication review, and the use of patient decision aids.

  4. Obesity prevention (CG43)

    This guideline covers preventing children, young people and adults becoming overweight or obese. It outlines how the NHS, local authorities, early years’ settings, schools and workplaces can increase physical activity levels and make dietary improvements among their target populations.

  5. VibraTip for testing vibration perception to detect diabetic peripheral neuropathy (MTG22)

    Evidence-based recommendations on VibraTip for testing vibration perception to detect diabetic peripheral neuropathy

  6. Bladder cancer: diagnosis and management (NG2)

    This guideline covers diagnosing and managing bladder cancer in people 18 and above referred from primary care with suspected bladder cancer, and those with newly diagnosed or recurrent bladder (urothelial carcinoma, adenocarcinoma, squamous-cell carcinoma or small-cell carcinoma) or urethral cancer.

  7. Meningitis (bacterial) and meningococcal septicaemia in under 16s: recognition, diagnosis and management (CG102)

    This guideline covers recognising, diagnosing and managing bacterial meningitis and meningococcal septicaemia (blood poisoning) in babies, children and young people under 16. It aims to reduce deaths and disability by promoting early recognition of symptoms and timely effective management.

  8. Eculizumab for treating atypical haemolytic uraemic syndrome (HST1)

    Evidence-based recommendations on eculizumab (Soliris) for treating atypical haemolytic uraemic syndrome in adults and children

  9. Chronic kidney disease in adults: assessment and management (CG182)

    This guideline covers the care and treatment of people with, or at risk of developing, chronic kidney disease. It aims to prevent or delay the progression of chronic kidney disease, reduce or prevent the development of complications, and reduce the risk of cardiovascular disease.

  10. Obesity: identification, assessment and management (CG189)

    This guideline covers identifying, assessing and managing obesity in children (aged 2 years and over), young people and adults. It aims to improve the use of bariatric surgery and very-low-calorie diets to help people who are obese to reduce their weight.

  11. The ReCell Spray‑On Skin system for treating skin loss, scarring and depigmentation after burn injury (MTG21)

    Evidence-based recommendations on the ReCell Spray-On Skin system for treating skin loss, scarring and depigmentation after burn injury

  12. Gallstone disease: diagnosis and management (CG188)

    This guideline covers diagnosing and managing gallstone disease in adults. It aims to reduce variation in care by promoting the most effective treatments, and to improve the advice given to people with gallstone disease before and after treatment.

  13. Acute heart failure: diagnosis and management (CG187)

    This guideline covers diagnosing and managing acute heart failure or possible acute heart failure in people aged 18 and over. It aims to improve the immediate care of someone who is acutely unwell as a result of heart failure.

  14. Drug allergy: diagnosis and management (CG183)

    This guideline covers diagnosing and managing drug allergy in all age groups. It aims to make it easier for professionals to tell when someone is having an allergic reaction, by specifying the key signs and patterns to look out for. It also makes recommendations on improving people’s understanding of their drug allergies, and ensuring these are recorded properly in their medical records.

  15. Transient loss of consciousness ('blackouts') in over 16s (CG109)

    This guideline covers assessment, diagnosis and referral for people over 16 who have had a transient loss of consciousness (TLoC; also called a blackout). It aims to improve care for people with TLoC by specifying the most effective assessments and recommending when to refer to a specialist.

  16. The MAGEC system for spinal lengthening in children with scoliosis (MTG18)

     April 2020: This guidance has been withdrawn while the MHRA conducts an investigation into the MAGEC system. The MHRA issued a Medical Device Alert MDA/2020/011 for all MAGEC systems. This is in response to the manufacturer’s latest Field Safety Notice and previous field safety notices for problems that may require early removal of devices and lead to inadequate treatment. The MHRA is not recommending prophylactic removal of devices but the supply of all MAGEC systems is suspended in the UK while the MHRA investigation is ongoing. The MHRA has set out the following actions: Do not implant MAGEC rods in the UK until further notice. Identify all patients implanted with a MAGEC System and ensure systems are in place to follow up these patients.

  17. Pressure ulcers: prevention and management (CG179)

    This guideline covers risk assessment, prevention and treatment in children, young people and adults at risk of, or who have, a pressure ulcer (also known as a bedsore or pressure sore). It aims to reduce the number of pressure ulcers in people admitted to secondary or tertiary care or receiving NHS care in other settings, such as primary and community care and emergency departments.

  18. Psychosis and schizophrenia in adults: prevention and management (CG178)

    This guideline covers recognising and managing psychosis and schizophrenia in adults. It aims to improve care through early recognition and treatment, and by focusing on long-term recovery. It also recommends checking for coexisting health problems and providing support for family members and carers.

  19. Varicose veins: diagnosis and management (CG168)

    This guideline covers diagnosing and managing varicose veins in people aged 18 and over. It aims to ensure that people understand the options for treating varicose veins and that healthcare professionals know when to refer people for specialist assessment and treatment.

  20. Falls in older people: assessing risk and prevention (CG161)

    This guideline covers assessment of fall risk and interventions to prevent falls in people aged 65 and over. It aims to reduce the risk and incidence of falls and the associated distress, pain, injury, loss of confidence, loss of independence and mortality.

  21. Stroke rehabilitation in adults (CG162)

    This guideline covers stroke rehabilitation for adults and young people aged 16 and over who have had a stroke with continuing impairment, activity limitation or participation restriction. It aims to improve rehabilitation for people who have had a stroke by specifying how stroke units and multidisciplinary stroke teams should be organised. It makes detailed recommendations on assessments and interventions for the functional difficulties caused by stroke.

  22. Social anxiety disorder: recognition, assessment and treatment (CG159)

    This guideline covers recognising, assessing and treating social anxiety disorder (also known as ‘social phobia’) in children and young people (from school age to 17 years) and adults (aged 18 years and older). It aims to improve symptoms, educational, occupational and social functioning, and quality of life in people with social anxiety disorder.

  23. Antisocial personality disorder: prevention and management (CG77)

    This guideline covers principles for working with people with antisocial personality disorder, including dealing with crises (crisis resolution). It aims to help people with antisocial personality disorder manage feelings of anger, distress, anxiety and depression, and to reduce offending and antisocial behaviour.

  24. Chronic kidney disease (stage 4 or 5): management of hyperphosphataemia (CG157)

    This guideline covers managing hyperphosphataemia in children, young people and adults with stage 4 or 5 chronic kidney disease. It makes recommendations on dietary management and phosphate binders, to reduce variation in care and the risk of hyperparathyroidism for people with chronic kidney disease.

  25. WatchBP Home A for opportunistically detecting atrial fibrillation during diagnosis and monitoring of hypertension (MTG13)

    Evidence-based recommendations on the WatchBP Home A for opportunistically detecting atrial fibrillation during diagnosis and monitoring of hypertension

  26. Neutropenic sepsis: prevention and management in people with cancer (CG151)

    This guideline covers preventing, identifying and managing neutropenic sepsis in children, young people and adults receiving treatment for cancer in the community and in secondary and tertiary care. It aims to reduce the risk of infection in people with neutropenia (low number of white blood cells) who are receiving anticancer treatment and improve management of neutropenic sepsis.

  27. Urinary incontinence in neurological disease: assessment and management (CG148)

    This guideline covers assessing and managing urinary incontinence in children, young people and adults with neurological disease. It aims to improve care by recommending specific treatments based on what symptoms and neurological conditions people have.

  28. Sickle cell disease: managing acute painful episodes in hospital (CG143)

    This guideline covers managing acute painful sickle cell episodes in children, young people and adults who present at hospital, from presentation until when they are discharged. It aims to reduce variation in how acute episodes are managed in hospital, focusing on effective, prompt and safe pain relief.

  29. Service user experience in adult mental health: improving the experience of care for people using adult NHS mental health services (CG136)

    This guideline covers the components of a good experience of service use. It aims to make sure that all adults using NHS mental health services have the best possible experience of care.

  30. Self-harm in over 8s: long-term management (CG133)

    This guideline covers the longer-term psychological treatment and management of self-harm in people aged 8 and over. It aims to improve the quality of care and support for people who self harm and covers both single and recurrent episodes of self-harm.